Table 2.
Propensity Score-Weighted Multivariable Cox Model for Clinical/Radiographic Progression-Free Survival (PFS).
| Hazard Ratio (95% C.I.) | P-value | |
|---|---|---|
|
| ||
| Treatment | ||
| Docetaxel Alone | 1.0 [Ref] | |
| Docetaxel + Prednisone | 0.53 (0.35 – 0.80) | 0.002 |
|
| ||
| Performance Status | ||
| 0 | 1.0 [Ref] | |
| 1 – 2 | 1.37 (1.003 – 1.87) | 0.05 |
|
| ||
| Presence of Pain | ||
| No | 1.0 [Ref] | |
| Yes | 1.15 (0.86 – 1.55) | 0.36 |
|
| ||
| PSA | 1 [Based upon 1 unit change] | 0.91 |
|
| ||
| Alkaline Phosphatase | 1 | 0.83 |
|
| ||
| Gleason Score | ||
| 6 | 1.0 [Ref] | |
| 7 | 0.57 (0.33 – 0.99) | 0.04 |
| 8 – 10 | 0.60 (0.36 – 0.99) | 0.05 |
|
| ||
| Visceral Metastasis: Liver | ||
| No | 1.0 [Ref] | |
| Yes | 1.22 (0.80 – 1.84) | 0.36 |
|
| ||
| Visceral Metastasis: Lung | ||
| No | 1.0 [Ref] | |
| Yes | 1.07 (067 – 1.69) | 0.78 |
|
| ||
| Prior Abi/Keto. | ||
| No | 1.0 [Ref] | |
| Yes | 0.73 (0.46 – 1.16) | 0.18 |
|
| ||
| Interaction | ||
| Treatment * Prior Abi/Keto | 1.79 (1.001 – 3.19) | 0.05 |